Federal agency faced obstacles to lower drug prices, memo shows
Global News
Health Minister Jean-Yves Duclos was warned that pharmaceutical companies had steadfastly refused to engage on drug-price reforms, a 2021 memo shows.
Health Minister Jean-Yves Duclos was warned that pharmaceutical companies had steadfastly refused to engage on drug-price reforms before he urged an independent federal agency to pause those reforms in favour of more consultation, a 2021 memo shows.
The memo, obtained by the NDP through the access-to-information law and shared with The Canadian Press, is a status report from the acting chair of the Patented Medicine Prices Review Board to the health minister about obstacles they were facing to lowering the price of drugs.
The review board is an arm’s-length federal agency tasked with regulating the cost of patented drugs in Canada to ensure they aren’t excessive, which includes looking at the price of similar medications in other countries.
In 2017, the government announced new rules to bring prices down by expanding the number of countries Canada compares with. Those changes were supposed to be introduced in 2020 but were delayed multiple times because of the COVID-19 pandemic before eventually coming into effect last July.
The agency was in the process of consulting on the finer details associated with the new rule in November when Duclos wrote to the acting chair and suggested the process be paused to give drug companies, patient groups, provincial ministers and himself more time to understand the changes.
The 2021 memo suggests the health minister knew pharmaceutical companies had been obstinate in the face of the changes, at least from the perspective of the agency.
“After five years, myriad policy proposals and many hundreds of hours of consultation, it would appear the pharmaceutical industry is simply not amenable to any measures that would further constrain its ability to sell patented medicines in Canada at free market prices,” the acting chair of the agency’s board at the time, Melanie Bourassa Forcier, wrote in the memo.
She said after 110 hours of meeting with members of the pharmaceutical industry to talk about the guidelines for the new rules, they “steadfastly refused to engage on the substance.”
The pill was approved by the U.S. Food and Drug Administration last month, a boon to Novo Nordisk as it looks to regain ground lost to U.S. rival Eli Lilly.
More water restrictions will be part of the 'new reality of water usage' warned Mayor Jeromy Farkas, as the city provided an update Monday on the rupture of a major water main.
'This decision protects children, respects families, and rebuilds trust in public health,' Health Secretary Robert F. Kennedy Jr. said in a statement.
To date, there have been six confirmed cases of chronic wasting disease in B.C. after it was first detected in B.C.'s Kootenay region in 2024.
In the week ending Dec. 20, one in four (25.6 per cent) of every influenza test conducted in the U.S. came back positive, the U.S. CDC said.
As of Dec. 29, Health Canada had received nine submissions seeking approval to make semaglutide, the active ingredient in Ozempic and Wegovy.
The B.C. Ministry of Transportation says Highway 16 linking Prince Rupert to communities in the east including Terrace has been shut in both directions due to flooding.
Time blindness has sparked a social media debate: Where is the line between a genuine condition and someone who is disorganized or just plain rude?